Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Dr. William Bosch, a Nano-pharmaceuticals Industry Leader, Joins iCeutica

Abstract:
iCeutica, Inc. announces nano-pharmaceuticals industry leader Dr. William Bosch has joined iCeutica, Inc. Until recently, Dr. Bosch was a senior member of the research and development management team at Elan Corporation responsible for Elan's NanoCrystal® Technology and the related drug reformulation and delivery business.

Dr. William Bosch, a Nano-pharmaceuticals Industry Leader, Joins iCeutica

Philadelphia, PA | Posted on September 12th, 2007

Dr. Bosch brings more than fifteen years of scientific innovation, leadership and team-building experience in pharmaceutical product development and drug delivery, having been a co-inventor, or having played a key role in the development of four of the five nano-particulate based drugs approved by the FDA in the last decade. His roles at Elan have encompassed basic research into nano-pharmaceuticals production, formulation science, regulatory strategy and IP prosecution. Dr. Bosch is widely regarded as a leader in the fields of drug delivery and manufacturing of nano-particles for pharmaceutical applications.

Dr. Bosch joins the team which is advancing a number of reformulated products into the clinic, utilizing iCeutica's proprietary Encapsulated Organic Nanoparticle (EON™) Platform. In addition to iCeutica's pipeline, these products include drugs reformulated under the recent collaboration with Iroko Pharmaceuticals as well as those being developed by Spree Pharma A/S, an iCeutica joint venture company.

"We are very pleased to have Dr. Bosch join us at this exciting period of the Company's growth. We are in the process of scaling up the EON platform in preparation for clinical trials and commercial manufacturing. Dr Bosch's unrivalled experience with nano-reformulation technologies will provide a significant boost to our regulatory and customer engagements," stated iCeutica CEO, Matt Callahan.

"iCeutica's EON platform is broadly applicable to a wide range of poorly soluble drug compounds and provides a novel and exciting approach to drug formulation development and drug product manufacturing. I am delighted to be joining the iCeutica team and look forward to working with them and our partners to maximize the potential of this important new technology," said Dr. Bosch.

####

About iCeutica, Inc.
iCeutica commercializes products developed utilizing its proprietary EON™ Platform. EON is an enabling reformulation technology which applies simple and scalable processes to reformulate development stage and marketed products with solubility, delivery or bioavailability challenges.

For more information, please click here

Contacts:
iCeutica, Inc.
Lisa Gray, EVP Corporate Development
+1-267-765-3233

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

Announcements

A step closer to understanding quantum mechanics: Swansea University’s physicists develop a new quantum simulation protocol October 22nd, 2017

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project